Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

PRIMARY OBJECTIVES: I. To determine efficacy of this novel combination in newly diagnosed patients with multiple myeloma. SECONDARY OBJECTIVES: I. To determine the toxicity of this novel combination regimen in previously treated patients and newly diagnosed patients with multiple myeloma. OUTLINE: Patients receive cyclophosphamide intravenously (IV) or orally (PO) over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of treatment, patients are followed up every 3 months for 2 years, then annually up to 5 years.